Can we predict the best RA drug? new study seeks answers

NCT ID NCT03414502

Recruiting now Knowledge-focused Sponsor: University of Nebraska Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking for clues to predict how well different rheumatoid arthritis (RA) drugs will work in individual patients. Researchers will give 400 adults with RA one or more standard medications and track their response over 16 weeks. The goal is to find genetic or other factors that help doctors choose the most effective treatment sooner.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: disease-modifying antirheumatic drugs (DMARDs) including methotrexate, abatacept, adalimumab, azathioprine, baricitinib, and others
What this could lead to: If successful, this could help doctors choose the right rheumatoid arthritis drug for each person, leading to faster and more effective treatment.
What could go wrong: This is an early-stage study focused on finding predictors, not testing a new treatment. The results may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

University of Nebraska Medical Center
RECRUITING

Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.